Carl L. Gordon, Director, 10% Owner at Kinnate Biopharma Inc. (KNTE), bought 2,692,684 shares at $2.62 ($7.0M) on 2023-05-01, disclosed to the SEC on 2023-05-02.
Open-market purchase of $7.0M KNTE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.55 | 60,997 | $156K | 2.2% |
| 2 | $2.55 | 60,997 | $156K | 2.2% |
| 3 | $2.55 | 60,998 | $156K | 2.2% |
| 4 | $2.55 | 60,998 | $156K | 2.2% |
| 5 | $2.55 | 228,754 | $583K | 8.3% |
| 6 | $2.55 | 228,754 |
| $583K |
| 8.3% |
| 7 | $2.62 | 124,544 | $326K | 4.6% |
| 8 | $2.62 | 124,544 | $326K | 4.6% |
| 9 | $2.62 | 124,545 | $326K | 4.6% |
| 10 | $2.62 | 124,545 | $326K | 4.6% |
| 11 | $2.62 | 467,068 | $1.2M | 17.4% |
| 12 | $2.62 | 467,068 | $1.2M | 17.4% |
| 13 | $2.67 | 58,826 | $157K | 2.2% |
| 14 | $2.67 | 58,826 | $157K | 2.2% |
| 15 | $2.67 | 220,610 | $589K | 8.4% |
| 16 | $2.67 | 220,610 | $589K | 8.4% |
| Total | $2.61 avg | 2,692,684 | $7.0M | 100% |
| Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| CMPX | SELL | 2025-04-11 | $11.4M | — | Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |